News Bridge Biotherapeutics, Inc.

Equities

A288330

KR7288330004

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-19 EDT			5-day change	1st Jan Change
2,140 ^KRW	-3.60%		-7.16%	-34.86%

03-28	Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade	CI
03-26	Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade	03-28	CI
Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology	03-26	CI
Bridge Biotherapeutics, Inc. announced that it has received KRW 1.99999872 billion in funding	01-21	CI
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 1.99999872 billion in funding	01-11	CI
Gpcr Therapeutics, Inc. Collaborates with Bridge Biotherapeutics, Inc. to Pursue Joint Development and Commercialization of the Combination Therapy	12-14	CI
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC	23-10-30	CI
Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis	23-10-25	CI
Bridge Biotherapeutics, Inc.(KOSDAQ:A288330) dropped from S&P Global BMI Index	23-09-18	CI
Bridge Biotherapeutics to Present at the 2023 BIO International Convention	23-05-30	AQ
Bridge Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Bridge Biotherapeutics Inc. Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting	23-04-18	CI
Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis	23-04-12	CI
Bridge Biotherapeutics announces preclinical study of self-discovered 4th generation lung cancer targeted therapy at AACR conference in the US	23-03-16	AQ
Bridge Biotherapeutics Presents Phase 2A Clinical Trial Results for BBT-401	23-02-20	CI
Bridge Biotherapeutics, Inc. Initiates Phase 2 Clinical Trial of BBT-877 in Patients with Idiopathic Pulmonary Fibrosis	22-11-07	CI
Bridge Biotherapeutics, Inc. Presents Non-Clinical Study Results for 2 IPF Candidates at the IPF Summit 2022	22-09-01	CI
Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877	22-08-15	CI
Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022	22-08-09	CI
Bridge Biotherapeutics : Material Management Information related to Judgment of Investment (US FDA approval of BBT-877 phase 2 clinical trial plan for the treatment of Idiopathic Pulmonary Fibrosis (IPF))	22-07-21	PU
Bridge Biotherapeutics : Organization of Investor Relations Event	22-07-18	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Bridge Biotherapeutics, Inc.

Equities

A288330

KR7288330004

Summary

Filters